The European Commission said the size of the fine, amounting to 10% of Illumina’s global revenue and the maximum allowed under EU merger rules for such infringements, underscored the seriousness of the offense and aimed to deter such conduct.
https://www.pharmalive.com/wp-content/uploads/2022/09/ReutersIllumina9-20-2022.jpg8031200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-07-12 10:28:172023-07-12 10:35:58Illumina fined a record $476 million by EU over Grail deal
